ProMIS Neurosciences Inc. Market Cap ($7.34 Million)
Market Cap & Net Worth: ProMIS Neurosciences Inc. (PMN)
ProMIS Neurosciences Inc. market cap. ProMIS Neurosciences Inc. (NASDAQ:PMN) has a market capitalization of $7.34 Million ($7.34 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27679 globally and #5729 in its home market, demonstrating a -57.69% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ProMIS Neurosciences Inc.'s stock price $3.41 by its total outstanding shares 2152444 (2.15 Million). Also see ProMIS Neurosciences Inc. (PMN) cash conversion ratio for how efficiently the company converts equity into cash flow.
ProMIS Neurosciences Inc. Market Cap History (2015–2026)
ProMIS Neurosciences Inc. market cap history from 2015 to 2026. Data shows change from $5.17 Million to $7.34 Million (-1.87% CAGR). Check current stock price of ProMIS Neurosciences Inc. for real-time trading data and today's change.
Index Memberships
ProMIS Neurosciences Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #787 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2538 of 3165 |
Weight: ProMIS Neurosciences Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ProMIS Neurosciences Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ProMIS Neurosciences Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ProMIS Neurosciences Inc. (PMN) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1147.80x
ProMIS Neurosciences Inc.'s market cap is 1147.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.17 Million | $14.37K | -$1.53 Million | 359.61x | N/A |
| 2016 | $12.91 Million | $2.00K | -$2.57 Million | 6450.62x | N/A |
| 2017 | $21.95 Million | $7.87K | -$4.79 Million | 2790.13x | N/A |
| 2018 | $25.83 Million | $348.74 | -$7.46 Million | 74064.71x | N/A |
| 2019 | $16.79 Million | $1.20K | -$7.40 Million | 13967.61x | N/A |
| 2020 | $10.33 Million | $1.56K | -$5.66 Million | 6601.75x | N/A |
| 2021 | $14.21 Million | $8.14K | -$9.66 Million | 1745.50x | N/A |
| 2022 | $9.34 Million | $8.14K | -$18.06 Million | 1147.80x | N/A |
Competitor Companies of PMN by Market Capitalization
Companies near ProMIS Neurosciences Inc. in the global market cap rankings as of November 4, 2026. Also see balance sheet size of ProMIS Neurosciences Inc. for a full breakdown of the balance sheet.
Key companies related to ProMIS Neurosciences Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of ProMIS Neurosciences Inc. (2015–2026)
Market capitalization of ProMIS Neurosciences Inc. from 2015 to today. Between 2015 and today, ProMIS Neurosciences Inc.'s market cap moved from $5.17 Million to $ 7.34 Million, with a yearly change of -1.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.34 Million | -50.04% |
| 2025 | $14.69 Million | +620.09% |
| 2024 | $2.04 Million | -17.58% |
| 2023 | $2.48 Million | -73.50% |
| 2022 | $9.34 Million | -34.24% |
| 2021 | $14.21 Million | +37.50% |
| 2020 | $10.33 Million | -38.46% |
| 2019 | $16.79 Million | -35.00% |
| 2018 | $25.83 Million | +17.65% |
| 2017 | $21.95 Million | +70.00% |
| 2016 | $12.91 Million | +150.00% |
| 2015 | $5.17 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of ProMIS Neurosciences Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.34 Million USD |
| MoneyControl | $7.34 Million USD |
| MarketWatch | $7.34 Million USD |
| marketcap.company | $7.34 Million USD |
| Reuters | $7.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product c… Read more